What is NDC 25021-239?

25021-239 is the product NDC for Gemcitabine, Gemcitabine hydrochloride 38 mg/mL injection, solution, listed with the FDA by Sagent Pharmaceuticals. It has 3 package NDCs, shown above in 10- and 11-digit form.

Sagent Pharmaceuticals, NDC labeler code 25021. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Gemcitabine?

24 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Gemcitabine NDC 25021-239 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)25021-239Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25021-0239Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
25021-239-05	2502102390525021023905	1 VIAL in 1 CARTON (25021-239-05) / 5.26 mL in 1 VIALMarketed from Jan 15, 2019
25021-239-26	2502102392625021023926	1 VIAL in 1 CARTON (25021-239-26) / 26.3 mL in 1 VIALMarketed from Jan 15, 2019
25021-239-52	2502102395225021023952	1 VIAL in 1 CARTON (25021-239-52) / 52.6 mL in 1 VIALMarketed from Jan 15, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Gemcitabine
Generic name (nonproprietary): gemcitabine
Active ingredients: Gemcitabine hydrochloride — 38 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Sagent PharmaceuticalsNDC labeler code 25021
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209077
Marketing start: Jan 15, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 25021-239_adf9b715-8cef-4a0d-ba30-d948b2b04272SPL ID adf9b715-8cef-4a0d-ba30-d948b2b04272SPL set ID 22af3507-4b4f-4cad-9d61-89ffc4aabbc7RxCUI 1720960, 1720975, 1720977UNII U347PV74IL
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N425021023905 followed by a unit qualifier and the quantity

Package 25021-0239-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 3, 2025.

Indications (excerpt from the label)

Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 25021-239

What is NDC 25021-239?: 25021-239 is the product NDC for Gemcitabine, Gemcitabine hydrochloride 38 mg/mL injection, solution, listed with the FDA by Sagent Pharmaceuticals. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Gemcitabine.
What is the active ingredient?: Gemcitabine hydrochloride.
Who is the labeler?: Sagent Pharmaceuticals, NDC labeler code 25021. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Gemcitabine?: 24 other product NDCs are listed under this name. See all Gemcitabine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Gemcitabine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Gemcitabine	Gemcitabine hydrochloride 38 mg/mL	Injection, SolutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9340	00143-9340-01
Gemcitabine	Gemcitabine hydrochloride 38 mg/mL	Injection, SolutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9341	00143-9341-01
Gemcitabine	Gemcitabine hydrochloride 38 mg/mL	Injection, SolutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9342	00143-9342-01
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 38 mg/mL	Injection, SolutionIntravenous	Meitheal Pharmaceuticals Inc.	71288-117	71288-0117-0671288-0117-2871288-0117-54
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 200 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar Rx LLC	16714-909	16714-0909-01
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 1 g/1	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar Rx LLC	16714-930	16714-0930-01
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 200 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous	Meitheal Pharmaceuticals Inc.	71288-113	71288-0113-10
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 1 g/1	Injection, Powder, Lyophilized, For solutionIntravenous	Meitheal Pharmaceuticals Inc.	71288-114	71288-0114-50
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 200 mg/5.26mL	Injection, SolutionIntravenous	Mylan Institutional LLC	67457-616	67457-0616-10
Gemcitabinegemcitabine hydrochloride	Gemcitabine hydrochloride 1 g/26.3mL	Injection, SolutionIntravenous	Mylan Institutional LLC	67457-617	67457-0617-30

All 25 Gemcitabine NDCs